Background: Previous studies have demonstrated a strong inverse
INTRODUCTION
A large body of evidence suggests an unusual relationship between cancer and neurodegenerative disorders [1, 2] . Recent epidemiologic studies have found that a history of cancer is associated with a 35%-60% reduced risk of Alzheimer's disease (AD), and similarly, AD is associated with a 12%-71% reduced risk of overall cancer [3] [4] [5] [6] [7] [8] . These findings are not entirely due to survival bias, as they are seen both in survivors and non-survivors, and the inverse association is seen both before and after diagnosis of either disease [5] . Several meta-analyses have confirmed the association [9, 10] . In contrast to its relationship with AD, cancer is not associated with a lower risk of vascular-type dementia, and in fact has been positively associated with the development of cerebrovascular disease [3, 8] . Such an inverse association is biologically plausible, as AD and cancer share a number of genes and pathways that are expressed in opposite directions [11] .
While these findings are intriguing, epidemiologic studies of the association between two severe age-related diseases are innately complex [12] , and it is difficult to adequately account for bias and confounding [13] . That a history of cancer might protect against AD also seems counterintuitive because cancer treatments, and cancer itself, have been associated with cognitive impairment [14] [15] [16] . Furthermore, there is substantial positive overlap between the two conditions, including dysregulation of energy metabolism, inappropriate entry into cell cycle, inflammation and oxidative stress.
What is needed to take this investigation further are studies that determine whether markers of AD or cancer provide substantive evidence of this inverse comorbidity at a structural and functional level. 
MATERIALS AND METHODS

Study Population
The study included participants from the FHS Offspring cohort [24] , 
Outcome Assessment
Cognitive function Standard test administration and scoring procedures, as described in previous FHS publications, were used [26] .
Structural brain aging
Brain MRI techniques used in the FHS have been described previously [27] . Briefly, a 1 or 1.5-T Seimens Magnetom scanner was used to acquire three-dimensional T1 and double echo proton density and T2 coronal All measures are expressed as a percentage of total cranial volume to adjust for head size. Also computed was white matter hyperintensity volume (WMHV). To identify white matter hyperintensities, the first and second echo images from T2 sequences were summed and a segmentation threshold was determined as 3.5 standard deviations in pixel intensity greater than the mean of the fitted distribution of brain parenchyma [28] . This technique has been previously validated [29] .
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Covariate Measurement
The following variables were assessed at the seventh Offspring clinic examination: diabetes, hypertension, history of cardiovascular disease (CVD), current cigarette smoking, and APOE4 carrier status.
Statistical Analyses
Descriptive statistics (mean, median, frequency) were calculated for all outcome variables. HVOT, Trails B, THV, and WMHV were natural log (ln) transformed to improve normality. Linear regression models were constructed to examine the association between cancer history (any cancer, basal/squamous skin cancer, any cancer excluding basal/squamous skin cancer, prostate cancer, and breast cancer) and each of the NP and MRI outcomes. All cancer groups were compared to a common referent group of participants with no history of cancer. For all regression models, ln Trails B was re-signed so that higher scores indicate better performance, to be consistent with the directionality of the other NP tests. Model 1 adjusted for age, sex, education (no high school degree, high school degree, college degree, greater than college degree), and time interval between cancer exposure and NP/MRI exam. Model 2 was further adjusted for cardiovascular risk factors (hypertension, diabetes, history of cardiovascular disease, smoking), and ApoE4 carrier status (presence of ≥1 ApoE4 alleles). All models for the MRI outcomes were additionally adjusted for age-squared due to the non-linear association between age and brain volume measures [27] . A p-value of <0.05 was considered statistically significant. All statistical analyses were performed using SAS version 9.4 (Cary, NC, USA). • Diabetes, n (%) 201 (11.6) 28 (11.7)
RESULTS
Study Sample Characteristics
• Hypertension, n (%) 716 (40.0) 124 (49.2)
• Current smoker, n (%) 235 (13.1) 18 (7.1)
• History of CVD, n (%) 162 (9.1) 39 (15.5)
Neuropsychological Test Measures
• Logical Memory Likewise, in a case-control analysis including 1,198 members of both the original and offspring FHS cohorts, patients with probable AD and any type of dementia had a 61% and 56% decreased risk of developing cancer, respectively [8] . Given that these results have been replicated in other large epidemiological studies [3] [4] [5] [6] [7] , the notion is that there are structural and functional substrate level changes that underlie or explain these observed protective effects. That we found better preclinical executive function may illustrate the heterogeneity of AD and would align with a potential vascular etiology consistent with Zlokovic's two-hit vascular hypothesis and the increasing evidence of a preclinical vascular pathway to AD [30] .
Further, the inverse epidemiological association between some cancers and AD has led to an examination of the genetic and biologic links between the two conditions [31] . studies have not shown any structural differences at baseline [38] .
Additional studies have found that patients with cancer have increased pre-treatment frontoparietal activation compared to healthy controls [15, 39] , especially in prefrontal regions, suggesting a subtle working memory impairment and recruitment of additional brain areas for compensation. Our finding of a decrement in the verbal learning task in the absence of other memory test differences may reflect this working memory impairment. Cancer treatments, such as chemotherapy and hormonal therapy, have also been extensively studied for their impact on brain structure and function. Multiple studies have shown receipt of chemotherapy to be related to diffuse decrease in gray and white matter volume, generally persisting long-term after treatment is completed [16, 38] . Functional MRI studies related to working and verbal memory tasks have found regions of hypoactivation, especially in the prefrontal cortex, inferior frontal cortex, medial temporal lobe, and posterior parietal cortex, at up to more than 10 year post-treatment [40, 41] , although one study found a return to pre-treatment baseline at one year [15] . Similarly, receipt of hormonal therapy has been found to be associated with worse performance on tests involving learning, memory, executive function, and processing speed [42] , with deficits lasting over Adv Geriatr Med Res. 2019;1:e190006. https://doi.org/10.20900/agmr20190006 the long-term, but formal tests involving MRI imaging remain to be pursued.
Strengths of our study include its measurement of cancer, cognition, and structural brain imaging in a well-defined cohort with long-term follow-up. Our lack of information on cancer treatment is a major limitation, as we are not able to look specifically at those who received chemotherapy or hormonal therapy. Another limitation is the small sample sizes for individual cancer types, limiting any conclusions that can be drawn for these groups. It should be emphasized that our study focuses on the results of cognitive population screening, and we excluded those diagnosed with clinical dementia and other neurologic disorders, leaving a study sample that was biased toward little to no cognitive impairment. Further, the study sample is highly educated and predominantly white, limiting the generalizability of these results to other ethnic or racial groups.
CONCLUSIONS
What we can conclude is that in this cohort of healthy middle-aged adults, there is insufficient evidence to relate history of invasive cancer with better indices of cognitive or neuroimaging markers. This is particularly interesting when considered alongside studies that show protective benefits of cancer on AD and dementia. Future work should examine the association between cancer and other biomarkers of AD including β-amyloid, tau, and markers of inflammation and neuronal metabolism, as well as more sensitive metrics to changes in cognition and neuroimaging, particularly related to white matter integrity.
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